<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02625779</url>
  </required_header>
  <id_info>
    <org_study_id>NARSAD_Bipolar</org_study_id>
    <nct_id>NCT02625779</nct_id>
  </id_info>
  <brief_title>Combined Cytidine and Creatine-containing Drug in the Treatment of the Bipolar Depression</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Trial of Combined Cytidine- and Creatine-containing Drug and Dietary Supplement in the Treatment of the Bipolar Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ewha Womans University Mokdong Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ewha Womans University Mokdong Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is aimed to investigate the efficacy and safety of the creatine and cytidine
      augmentation in treating bipolar depression and to evaluate changes in relevant brain
      biochemical metabolism using proton and phosphorous magnetic resonance spectroscopy.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The research project has been cancelled before any participants were enrolled.
  </why_stopped>
  <start_date type="Anticipated">March 1, 2016</start_date>
  <completion_date type="Anticipated">April 30, 2017</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in symptoms of bipolar depression</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>assessed with structured clinical interview</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in depressive symptoms</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>assessed with structured clinical interview</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in brain Glx (glutamate+glutamine) level</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>assessed with proton magnetic resonance spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in brain phosphocreatine level</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>assessed with phosphorous magnetic resonance spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Baseline through 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Depression, Bipolar</condition>
  <arm_group>
    <arm_group_label>Valproate and Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Valproate: 300mg/day for 8 weeks Placebo: for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valproate and Cytidine-containing Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Valproate: 300mg/day for 8 weeks Cytidine-containing Drug: 2g/day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valproate and Creatine-containing Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Valproate: 300mg/day for 8 weeks Creatine-containing Drug: 3g/day for the first week 5g/day for week 2-8</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproate and Placebo</intervention_name>
    <arm_group_label>Valproate and Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproate and Cytidine-containing Drug</intervention_name>
    <arm_group_label>Valproate and Cytidine-containing Drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproate and Creatine-containing Drug</intervention_name>
    <arm_group_label>Valproate and Creatine-containing Drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 19-65 years

          -  Bipolar disorder I or II (DSM-IV-TR) with current depressive episode

          -  Informed consent

        Exclusion Criteria:

          -  Use of medication for bipolar depression or other psychotropic drugs

          -  Current Axis I mental disorders other than bipolar depression based on structured
             clinical interview

          -  Current borderline or antisocial personality disorder based on structured clinical
             interview

          -  Major medical or neurological illnesses (epilepsy, multiple sclerosis, brain tumor,
             cerebrovascular disease, etc)

          -  Hypersensitivity to divalproate or valpromide

          -  Diagnosis of porphyria

          -  Current or past liver diseases

          -  Severe dysfunction in liver or pancreas

          -  Use of mefloquine

          -  Alcohol or substance abuse/dependence

          -  Intelligence quotient of 80 or below

          -  Contraindications to magnetic resonance imaging

          -  Pregnancy or breastfeeding

          -  Allergy or intolerance to the study drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ewha Womans University Mokdong Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2015</study_first_submitted>
  <study_first_submitted_qc>December 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2015</study_first_posted>
  <last_update_submitted>February 8, 2018</last_update_submitted>
  <last_update_submitted_qc>February 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ewha Womans University Mokdong Hospital</investigator_affiliation>
    <investigator_full_name>In Kyoon Lyoo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Bipolar depression</keyword>
  <keyword>Cytidine</keyword>
  <keyword>Creatine</keyword>
  <keyword>Magnetic resonance spectroscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

